Now I have all the information needed to produce a calibrated, authoritative final review.

## Summary

This paper evaluates small language models (SLMs) and small vision-language models (SVLMs) against their larger, medically-adapted counterparts on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR). It uses zero-shot/few-shot ICL and LoRA fine-tuning, and introduces a "collapse analysis" framework measuring task adherence, hallucination rate, concept recall, and prompt robustness across model scales.

## Strengths

- **Practically important question with a well-chosen two-task design.** The paper asks whether small, deployable models can substitute for large medical LLMs — a question with direct implications for privacy, cost, and on-premise deployment. By evaluating both a pure NLP task (MeQSum) and a multimodal task (MIMIC-CXR), the paper reveals that the answer differs by modality: small LMs can be surprisingly competitive for text, but small VLMs consistently lag behind even after fine-tuning. This contrast is the paper's most informative empirical observation.

- **Clean, fairly-executed zero-shot ICL evaluation (Table 2).** The multi-prompt averaging protocol (five prompt variants per model) is methodologically sound, reducing prompt-engineering artifacts. The finding that SmolLM2-1.7B achieves BERTScore (0.9007) and MEDCON (0.271) competitive with 7–8B medical LMs (BioMistral-7B: 0.8857/0.295, OpenBioLLM-8B: 0.8938/0.336) is genuinely interesting and rests on a fair comparison where all models use the same ICL protocol.

- **The collapse analysis framework (Table 3) is a useful conceptual contribution.** Measuring hallucination rate, task adherence, prompt robustness, and concept recall as functions of model scale provides a structured lens for identifying degradation patterns. The observation that hallucination rates spike sharply at sub-billion scales (SmolLM2-360M: 18.3%, Gemma-3-270M: 75%) is a plausible and practically important hypothesis.

## Weaknesses

### Fatal
None.

### Major

- **The headline fine-tuning comparison is confounded and the claim overreaches.** The paper's central assertion — that "after LoRA fine-tuning, all small LMs outperformed large LMs across every metric" (line 231) — is based on comparing **LoRA-tuned small models against large models evaluated only with in-context learning, never fine-tuned.** Figure 3 and its associated table show "—" for the LoRA column of every large model (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B). This conflates model size *and* adaptation method simultaneously. The large models are already medically adapted through pre-training, so the comparison shows *small + task LoRA vs. large + medical pre-training + ICL* — a useful but imperfect comparison. However, the paper's sweepingly definitive language ("model scale can be traded for adapter efficiency without sacrificing quality," line 247) does not acknowledge this asymmetry. A design that either (a) applies LoRA to both small and large models, or (b) compares both in ICL-only settings, would support the claim. As presented, the reader cannot tell whether the advantage comes from fine-tuning or from the small model's architecture.

### Minor

- **Concrete errors in the experimental record.** Table 3 lists "SmolLM3-3B" (line 126), but the paper references the SmolLM2 family and no "SmolLM3" exists in the cited work. The body text refers to "MeQ-Small corpus" (line 231), whereas the dataset is defined as MeQSum throughout the rest of the paper. An unresolved "Table ?? " reference appears on line 219. These are not formatting artifacts — they are errors in the paper's body text and tables that suggest inconsistent record-keeping.

- **The "1B safety threshold" claim is undersupported by the data.** The collapse analysis (Table 3) contains 7 data points across 2 model families (SmolLM2: 3B, 1.7B, 360M, 135M; Gemma-3: 4B, 1B, 270M). The sharp hallucination spike is observed at exactly one model per family (SmolLM2-360M and Gemma-3-270M). Claiming a precise "threshold at approximately 1B parameters" (Table 3 caption) overstates what this data density can distinguish. The observed pattern is consistent with a degradation somewhere below 1.7B, but the specific cross-over point is not identifiable from these sparse measurements.

### Trivial

- **Minor internal inconsistency.** Section 3 states "We considered only SLMs with a maximum of 3 billion parameters" (line 76), yet the collapse analysis in Table 3 includes Gemma-3-4B (4B parameters). This does not affect the results but should be harmonized.

## Nice-to-Haves

- **Report variance or confidence intervals.** The test sets contain 250 samples — large enough to compute standard deviations or bootstrap intervals. Single-point scores make it hard to assess whether reported differences are meaningful.
- **The VLM comparison has the same asymmetry as the text case** (small VLMs fine-tuned on 10K MIMIC-CXR pairs; large VLMs not re-fine-tuned on the same subset). The paper's conclusion is appropriately cautious here (small VLMs still lag), so this does not undermine the finding, but it should be acknowledged.
- **Denser sampling of model scales** in the collapse analysis would strengthen the threshold claim.

## Removed Points

These points are flagged to be removed from the harsh critic's review; treat them with caution.

- **"Bio Mitral" appears in Figure 1 caption (lines 58, 61).** The paper correctly uses "BioMistral" everywhere in the body text and tables. This is a parser artifact from the embedded figure image — not an author error.
- **"Llama-3.2-16" appears in Figure 3.** This name appears in text extracted from the figure's embedded image and its derived table description. The paper correctly uses "LLaMA-3.2 (1B)" in the body text. Likely a parser artifact from image-to-text extraction.
- **Incomplete sentence at line 13.** "Traditionally, large-scale, domain-adapted language models (LLMs) like MedGemini... and MedPaLM2." is grammatically incomplete. This is almost certainly a formatting/parser artifact from the PDF extraction.
- **"MedGemini and MedPaLM2 are not the same class as the open-weight models used as baselines."** The introduction motivates the work using proprietary models; the experiments appropriately use the closest open-weight equivalents. This is standard practice, not a flaw.
- **"Table 4 is never explicitly referenced."** Table 4 is referenced at line 249 as "(Table 4)." The only issue is the "Table ??" placeholder on line 219, which is already captured as a Minor weakness.
- **VLM "fairness" criticism.** The reviewer notes the same asymmetry (small fine-tuned, large not) in the VLM section. However, the paper's conclusion here is *conservative* (small VLMs still lag), so the asymmetry does not distort the finding. This is at most a Nice-to-Have.
- **Generic requests** (e.g., "confidence intervals") — moved to Nice-to-Haves where appropriate.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Fix the fine-tuning comparison.** Either (a) apply the same LoRA protocol to the large medical LMs and compare all models on equal footing, or (b) reframe the fine-tuning section to explicitly acknowledge the asymmetry and avoid claiming that scale alone was traded for efficiency. The paper's zero-shot ICL results already provide a fair, informative comparison that partially supports the "small models are competitive" narrative without this confound.
2. **Correct the concrete errors:** "SmolLM3-3B" → consistent naming (SmolLM2-3B or explain the model), "MeQ-Small" → "MeQSum", "Table ??" → the correct table number.
3. **Caveat the safety threshold claim** as exploratory rather than establishing a precise 1B boundary, given the sparse data.

## Score and Decision

MY FINAL SCORE: <score>4</score>
MY FINAL DECISION: <decision>Reject</decision>